The Trump administration is preparing to impose tariffs of up to 100% on certain
imported medicines, potentially as soon as Thursday, targeting companies that
have not agreed to boost US manufacturing, according to people familiar with the
matter. The move follows earlier threats to penalize branded drug imports and is
based on a national security probe under Section 232 of the Trade Expansion Act.
Firms including Pfizer, AstraZeneca and Novo Nordisk have reached agreements to
invest in the US and cut prices in exchange for tariff relief, while countries
with trade deals may face lower, capped duties.
